GenSpera Receives Patent on Second Prostate-Targeting Oncology Drug
3/17/2011 8:27:38 AM
SAN ANTONIO--(BUSINESS WIRE)--GenSpera, Inc. (OTC.BB: GNSZ) announced that its patent application, entitled “Activation of Peptide Prodrugs by HK2,” has been issued by the United States Patent and Trademark Office (USPTO) as US Patent 7,906,477. The patent covers the composition of Ac-GKAFRR-L12ADT, a prodrug that is cleaved specifically by HK2, an enzyme secreted by prostate cancer cells, to deliver a potent thapsigargin derivative selectively to prostate cancers. Thapsigargin is the active ingredient in the GenSpera prodrug platform. Ac-GKAFRR-L12ADT is GenSpera’s second drug that specifically targets prostate cancer.